Drugs / MVA-HBV
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04778904 | Dec 2020 → Feb 2023 | chronic hepatitis B virus infection | Barinthus Biotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT03866187 | Mar 2019 → Oct 2024 | chronic hepatitis B virus infection | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05343481 | Sep 2022 → Jan 2026 | chronic hepatitis B virus infection | Barinthus Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05276297 | Mar 2022 → Aug 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-HBV | “1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.” NCT05276297 ↗ |
| Modality | Vaccine | “Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine” NCT04778904 ↗ |
| Route | Intramuscular | “by intramuscular injection in the deltoid of the non-dominant arm” NCT03866187 ↗ |